Avalon GloboCare (Nasdaq:ALBT) - Cotización, noticias y análisis

Resumen de acción ALBT

Avalon GloboCare Corp., junto con sus filiales, posee y explota propiedades inmobiliarias comerciales en Estados Unidos y China.

Acerca de la empresa

ALBT fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Recompensas

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($-7M)

No tiene una capitalización de mercado significativa ($3M)

Tiene menos de 1 año de cash runway

Volatilidad del precio de la acción en los últimos 3 meses

+ 1 riesgos adicionales

Competidores de Avalon GloboCare Corp.

Ucommune International

NasdaqCM:UK

US$1.7m

Tuxis

OTCPK:TUXS

US$2.6m

Rafael Holdings

NYSE:RFL

US$41.9m

New Concept Energy

NYSEAM:GBR

US$6.5m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Avalon GloboCare
Historical stock prices
Current Share Price	US$0.28
52 Week High	US$2.42
52 Week Low	US$0.25
Beta	0.27
1 Month Change	-14.06%
3 Month Change	-36.05%
1 Year Change	-85.45%
3 Year Change	-97.36%
5 Year Change	-98.87%
Change since IPO	-96.07%

Noticias y actualizaciones recientes

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Oct 06

Recent updates

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Oct 06

Have Insiders Been Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Shares This Year?

Jan 30

Is Avalon GloboCare (NASDAQ:AVCO) Using Too Much Debt?

Jan 04

What Percentage Of Avalon GloboCare Corp. (NASDAQ:AVCO) Shares Do Insiders Own?

Nov 30

Rentabilidad de los accionistas

	ALBT	US Real Estate	Mercado US
7D	-3.8%	5.7%	2.2%
1Y	-85.4%	11.5%	22.8%

Rentabilidad vs. Industria: ALBT obtuvo unos resultados inferiores a los del sector US Real Estate , que el año pasado arrojó un rendimiento del 10.7%.

Rentabilidad vs. Mercado: ALBT obtuvo unos resultados inferiores a los del mercado US, que fue del 21.9% el año pasado.

Volatilidad de los precios

Is ALBT's price volatile compared to industry and market?
ALBT volatility
ALBT Average Weekly Movement	11.7%
Real Estate Industry Average Movement	6.2%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de ALBT ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ALBT(12%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2016	5	David Jin	www.avalon-globocare.com

Avalon GloboCare Corp., junto con sus filiales, posee y explota propiedades inmobiliarias comerciales en Estados Unidos y China. La empresa desarrolla y suministra terapias celulares transformadoras, diagnósticos de precisión y servicios de laboratorio clínico. Sus principales candidatos son AVA-001, un CAR-T anti-CD19, que ha completado el primer ensayo clínico en humanos para la leucemia linfoblástica de células B en recaída/refractaria (R/R); y AVA-011, que ha completado los estudios preclínicos de laboratorio y se encuentra en la fase de desarrollo del proceso IND para generar células CAR-T AVA-011 de calidad cGMP.

Resumen de fundamentos de Avalon GloboCare Corp.

¿Cómo se comparan los beneficios e ingresos de Avalon GloboCare con su capitalización de mercado?
Estadísticas fundamentales de ALBT
Capitalización bursátil	US$3.03m
Beneficios(TTM)	-US$16.71m
Ingresos (TTM)	n/a

-0.4x

Ratio precio-ventas (PS)

-0.2x

Ratio precio-beneficio (PE)

¿Está ALBT sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ALBT
Ingresos	-US$7.33m
Coste de los ingresos	US$1.02m
Beneficio bruto	-US$8.35m
Otros gastos	US$8.36m
Beneficios	-US$16.71m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.50
Margen bruto	113.87%
Margen de beneficio neto	227.80%
Ratio deuda/patrimonio	113.6%

¿Cómo se ha desempeñado ALBT a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ALBT

Recompensas

Análisis de riesgos

Competidores de Avalon GloboCare Corp.

NasdaqCM:UK

US$1.7m

OTCPK:TUXS

US$2.6m

NYSE:RFL

US$41.9m

NYSEAM:GBR

US$6.5m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Avalon GloboCare Corp. Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Corp. announced delayed annual 10-K filing

Third quarter 2023 earnings released: US$0.14 loss per share (vs US$0.56 loss in 3Q 2022)

Avalon Globocare Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market as Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Share price stability

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Recent updates

Avalon GloboCare Corp. Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Corp. announced delayed annual 10-K filing

Third quarter 2023 earnings released: US$0.14 loss per share (vs US$0.56 loss in 3Q 2022)

Avalon Globocare Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market as Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Share price stability

We Think Some Shareholders May Hesitate To Increase Avalon GloboCare Corp.'s (NASDAQ:ALBT) CEO Compensation

Avalon GloboCare Corp., Annual General Meeting, Oct 12, 2023

Second quarter 2023 earnings released: US$0.25 loss per share (vs US$0.23 loss in 2Q 2022)

Avalon GloboCare Corp. announced delayed 10-Q filing

Full year 2022 earnings released: US$1.28 loss per share (vs US$1.07 loss in FY 2021)

Avalon GloboCare Corp. announced that it expects to receive $11 million in funding

Avalon GloboCare Regains Compliance with the Minimum Bid Requirement

Avalon Globocare Appoints Lourdes Felix, to Its Board of Directors

Avalon GloboCare Corp., Annual General Meeting, Dec 29, 2022

Third quarter 2022 earnings released: US$0.056 loss per share (vs US$0.024 loss in 3Q 2021)

Insufficient new directors

Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into an agreement to acquire 60% stake in Laboratory Services MSO, LLC for $31 million.

We Think Avalon GloboCare (NASDAQ:AVCO) Has A Fair Chunk Of Debt

Avalon GloboCare Receives Second Letter from the Staff of Nasdaq

Second quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 2Q 2021)

Avalon GloboCare Corp. Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer

Avalon GloboCare Corp. announced that it has received $3.718943 million in funding

Insufficient new directors

Would Avalon GloboCare (NASDAQ:AVCO) Be Better Off With Less Debt?

Avalon GloboCare Corp. Appoints Hongxing Liu to Scientific and Clinical Advisory Board

First quarter 2022 earnings released: US$0.023 loss per share (vs US$0.028 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings released: US$0.11 loss per share (vs US$0.16 loss in FY 2020)

Does Avalon GloboCare (NASDAQ:AVCO) Have A Healthy Balance Sheet?

Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies

Third quarter 2021 earnings released: US$0.024 loss per share (vs US$0.04 loss in 3Q 2020)

Here's Why Avalon GloboCare (NASDAQ:AVCO) Can Afford Some Debt

Director William Stilley has joined 3rd company board

Second quarter 2021 earnings released: US$0.028 loss per share (vs US$0.039 loss in 2Q 2020)

Avalon GloboCare Corp.(NasdaqCM:AVCO) dropped from Russell Microcap Value Index

Avalon GloboCare Corp. (NasdaqCM:AVCO) entered into a definitive agreement to acquire Hebei Senlang Biotechnology Inc., Ltd. for approximately CNY 640 million.

Avalon Globocare to acquire SenlangBio in all-stock deal

First quarter 2021 earnings released: US$0.028 loss per share (vs US$0.043 loss in 1Q 2020)

Is Avalon GloboCare (NASDAQ:AVCO) A Risky Investment?

Full year 2020 earnings released: US$0.16 loss per share (vs US$0.24 loss in FY 2019)

A Look At Avalon GloboCare's (NASDAQ:AVCO) Share Price Returns

New 90-day high: US$1.59

Have Insiders Been Buying Avalon GloboCare Corp. (NASDAQ:AVCO) Shares This Year?

New 90-day high: US$1.33

Is Avalon GloboCare (NASDAQ:AVCO) Using Too Much Debt?

What Percentage Of Avalon GloboCare Corp. (NASDAQ:AVCO) Shares Do Insiders Own?

Third quarter 2020 earnings released: US$0.04 loss per share

New 90-day low: US$1.12

Avalon GloboCare Provides Clinical Updates on its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC) Therapy Programs Following Successful Completion of Phase I AVA-001 Clinical Trial

New 90-day low: US$1.15

New 90-day low - US$1.54

First half earnings released

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Avalon GloboCare Corp.

-0.4x

-0.2x

Beneficios e Ingresos